aTyr Pharma, Inc.
ATYRHealthcare|Biotechnology|US
$6.35
+0.32 (+5.31%)
Tangible Book / Share
$13.76
Cash / Share
$20.46
Financials
Financial Snapshot
Market Cap
$15.6M
Enterprise Value
-$23.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$53.3M
Cash & Investments
$50.3M
Net Cash
$39.3M
Free Cash Flow (TTM)
-$43.9M
Operating CF (TTM)
-$43.6M
Debt/Equity
0.32
Cash Runway & Burn Rate
Cash on Hand
$50.3M
Quarterly Burn
$10.9M
Monthly Burn
$3.6M
Est. Runway
~4.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $72.1M | $85.1M | $49.5M | $31.1M | $31.7M | $107.9M | $66.1M | $98.2M | $72.1M | $78.7M | $50.3M | |
| Operating Cash Flow | -$52.9M | -$42.4M | -$31.1M | -$20.0M | -$15.3M | -$33.1M | -$41.9M | -$33.2M | -$69.1M | -$62.0M | -$43.6M | |
| Free Cash Flow | -$53.5M | -$43.7M | -$31.7M | -$20.1M | -$15.5M | -$33.3M | -$43.5M | -$37.4M | -$69.2M | -$62.1M | -$43.9M | |
| Capital Expenditure | -$600.0K | -$1.3M | -$594.0K | -$79.0K | -$202.0K | -$192.0K | -$1.6M | -$4.2M | -$65.0K | -$77.0K | -$287.0K | |
| Financing Cash Flow | $4.7M | $52.7M | -$4.2M | $1.3M | $16.1M | $110.0M | $5.5M | $66.2M | $39.9M | $66.0M | $371.0K |
R&D Spending
R&D (TTM)
$35.4M
R&D Intensity
—
R&D Growth vs Prior
-41.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $422.0K | $10.5M | $0.00 | $10.4M | $353.0K | $235.0K | $190.0K | $0.00 | |
| R&D Expense | $44.2M | $30.1M | $20.4M | $14.0M | $17.3M | $23.3M | $42.8M | $42.3M | $54.4M | $60.2M | $35.4M | |
| R&D % of Revenue | — | — | — | 3328.9% | 165.4% | — | 412.2% | 11981.0% | 23137.0% | 31694.2% | — | |
| SG&A | $14.2M | $16.4M | $11.7M | $9.4M | $9.1M | $10.8M | $12.3M | $13.0M | $13.8M | $17.6M | $20.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $422.0K | $10.5M | $0.00 | $10.4M | $353.0K | $235.0K | $190.0K | $0.00 | |
| Cost of Revenue | $900.0K | $713.0K | $746.0K | $14.0M | $17.3M | $1.3M | $1.7M | $0.00 | $0.00 | $1.6M | $799.0K | |
| Gross Profit | -$900.0K | -$713.0K | -$746.0K | -$13.6M | -$6.8M | -$1.3M | $8.7M | $353.0K | $235.0K | -$1.4M | -$799.0K | |
| R&D | $44.2M | $30.1M | $20.4M | $14.0M | $17.3M | $23.3M | $42.8M | $42.3M | $54.4M | $60.2M | $35.4M | |
| SG&A | $14.2M | $16.4M | $11.7M | $9.4M | $9.1M | $10.8M | $12.3M | $13.0M | $13.8M | $17.6M | $20.5M | |
| Operating Income | -$59.3M | -$47.1M | -$32.8M | -$23.0M | -$15.9M | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M | -$55.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$57.9M | -$48.2M | -$34.5M | -$23.8M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M | -$53.3M | |
| Net Income | -$57.9M | -$48.2M | -$34.5M | -$23.6M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M | -$53.3M | |
| EPS (Diluted) | -1368.00 | -1046.40 | -645.20 | -281.20 | -70.80 | -70.80 | -64.00 | -37.60 | -34.40 | -32.00 | -21.83 | |
| EBITDA | -$57.0M | -$46.4M | -$32.1M | -$21.6M | -$14.6M | -$32.5M | -$43.6M | -$47.7M | -$62.5M | -$72.6M | -$53.2M | |
| Shares Out. (M) | 0.04 | 0.05 | 0.05 | 0.08 | 0.23 | 0.48 | 0.71 | 1.34 | 1.86 | 2.32 | 2.46 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.4M | $21.1M | $23.0M | $9.2M | $17.0M | $2.3M | $10.0M | $22.5M | $11.1M | $10.7M | $50.3M | |
| Short-Term Investments | $33.8M | $64.0M | $26.6M | $21.9M | $14.7M | $105.6M | $56.2M | $75.6M | $61.1M | $67.9M | $0.00 | |
| Total Current Assets | $74.8M | $87.0M | $50.8M | $31.9M | $35.5M | $113.6M | $80.9M | $103.0M | $82.0M | $80.2M | $50.8M | |
| Total Assets | $80.5M | $89.4M | $52.7M | $36.2M | $38.7M | $115.5M | $95.8M | $120.7M | $96.8M | $94.2M | $59.8M | |
| Total Current Liabilities | $8.5M | $10.4M | $10.8M | $12.9M | $5.9M | $6.0M | $13.9M | $16.4M | $15.0M | $15.1M | $16.5M | |
| Long-Term Debt | $9.2M | $14.7M | $8.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.6M | |
| Total Liabilities | $17.7M | $25.1M | $19.1M | $15.2M | $7.2M | $6.4M | $24.5M | $30.2M | $27.0M | $26.9M | $26.0M | |
| Stockholders' Equity | $62.8M | $64.2M | $33.6M | $21.2M | $31.6M | $109.3M | $71.5M | $90.7M | $70.0M | $67.5M | $34.0M | |
| Retained Earnings | -$216.0M | -$264.2M | -$298.7M | -$322.3M | -$338.5M | -$372.3M | -$417.6M | -$468.0M | -$532.0M | -$606.2M | -$645.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.9M | -$42.4M | -$31.1M | -$20.0M | -$15.3M | -$33.1M | -$41.9M | -$33.2M | -$69.1M | -$62.0M | -$43.6M | |
| Capital Expenditure | -$600.0K | -$1.3M | -$594.0K | -$79.0K | -$202.0K | -$192.0K | -$1.6M | -$4.2M | -$65.0K | -$77.0K | -$287.0K | |
| Free Cash Flow | -$53.5M | -$43.7M | -$31.7M | -$20.1M | -$15.5M | -$33.3M | -$43.5M | -$37.4M | -$69.2M | -$62.1M | -$43.9M | |
| Investing Cash Flow | $33.5M | -$27.6M | $37.2M | $4.9M | $6.9M | -$91.6M | $47.2M | -$20.1M | $17.2M | -$5.1M | $49.0M | |
| Financing Cash Flow | $4.7M | $52.7M | -$4.2M | $1.3M | $16.1M | $110.0M | $5.5M | $66.2M | $39.9M | $66.0M | $371.0K | |
| Issuance of Stock | $163.0K | $42.5M | $379.0K | $9.3M | $25.2M | $110.0M | $5.5M | $66.5M | $40.3M | $66.4M | $895.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.0K | |
| Net Debt Issuance | $4.5M | $9.9M | -$4.7M | -$8.0M | -$9.1M | $0.00 | -$66.0K | -$394.0K | -$497.0K | -$539.0K | -$426.0K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $1.8M | $1.5M | $1.6M | $2.2M | $2.6M | $3.0M | $5.0M | $6.3M | |
| Net Change in Cash | -$14.6M | -$17.3M | $1.9M | -$13.8M | $7.7M | -$14.6M | $10.8M | $12.9M | -$12.0M | -$1.0M | $5.8M |
Dilution Tracker
Shares outstanding grew 915.1% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+915.1%
Stock Issuance (TTM)
$895.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.04 | 0.05 | 0.05 | 0.08 | 0.23 | 0.48 | 0.71 | 1.34 | 1.86 | 2.32 | 2.46 | |
| Change vs Prior % | — | 8.9% | 16.1% | 56.8% | 173.0% | 108.3% | 48.9% | 88.6% | 38.5% | 25.2% | 5.7% | |
| Stock Issuance | $163.0K | $42.5M | $379.0K | $9.3M | $25.2M | $110.0M | $5.5M | $66.5M | $40.3M | $66.4M | $895.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.0K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $1.8M | $1.5M | $1.6M | $2.2M | $2.6M | $3.0M | $5.0M | $6.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | -3228.9% | -65.4% | — | 83.7% | 100.0% | 100.0% | -717.4% | — | |
| Operating Margin % | — | — | — | -5445.0% | -152.2% | — | -446.8% | -15557.8% | -28899.6% | -40856.3% | — | |
| Net Margin % | — | — | — | -5593.1% | -155.2% | — | -436.5% | -14274.5% | -27243.8% | -39009.5% | — | |
| EBITDA Margin % | — | — | — | -5121.3% | -140.1% | — | -420.3% | -13500.3% | -26588.1% | -38192.1% | — | |
| FCF Margin % | — | — | — | -4761.1% | -148.3% | — | -419.1% | -10605.1% | -29440.0% | -32664.7% | — | |
| ROE % | -92.1% | -75.0% | -102.6% | -111.4% | -51.3% | -30.9% | -63.4% | -55.6% | -91.4% | -109.8% | -102.5% | |
| ROA % | -71.8% | -53.9% | -65.4% | -65.2% | -41.9% | -29.2% | -47.3% | -41.8% | -66.1% | -78.7% | -89.2% | |
| ROIC % | -82.0% | -56.1% | -66.1% | -70.1% | -47.2% | -30.8% | -56.0% | -52.0% | -81.7% | -96.5% | -128.1% | |
| R&D / Revenue % | — | — | — | 3328.9% | 165.4% | — | 412.2% | 11981.0% | 23137.0% | 31694.2% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 2377.5% | -100.0% | 0.0% | -96.6% | -33.4% | -19.1% | |
| Gross Profit | 0.0% | 20.8% | -4.6% | -1726.5% | 49.8% | 80.9% | 766.5% | -95.9% | -33.4% | -680.0% | |
| Operating Income | -24.6% | 20.6% | 30.4% | 30.0% | 30.8% | -113.8% | -36.4% | -18.3% | -23.7% | -14.3% | |
| Net Income | -20.6% | 16.7% | 28.4% | 31.6% | 31.3% | -108.1% | -34.3% | -11.1% | -27.1% | -15.8% | |
| EPS (Diluted) | 19.4% | 23.5% | 38.3% | 56.4% | 74.8% | 0.0% | 9.6% | 41.3% | 8.5% | 7.0% | |
| Operating Cash Flow | -43.7% | 19.9% | 26.7% | 35.6% | 23.5% | -116.2% | -26.6% | 20.7% | -108.1% | 10.3% | |
| Free Cash Flow | -42.7% | 18.3% | 27.5% | 36.5% | 22.8% | -114.6% | -30.8% | 14.0% | -84.8% | 10.3% | |
| R&D Expense | 28.2% | -32.0% | -32.2% | -31.1% | 23.1% | 34.5% | 84.0% | -1.2% | 28.6% | 10.8% | |
| SG&A Expense | 8.3% | 15.3% | -28.6% | -20.0% | -3.0% | 18.5% | 14.3% | 5.6% | 6.1% | 27.7% | |
| Total Assets | -37.9% | 11.0% | -41.0% | -31.4% | 7.0% | 198.3% | -17.1% | 26.0% | -19.7% | -2.8% | |
| Book Value / Share | -63.5% | -6.1% | -54.9% | -60.2% | -45.1% | 66.4% | -56.1% | -32.7% | -44.3% | -23.0% | |
| Debt | 85.5% | 106.9% | -18.8% | -26.8% | -80.9% | -38.5% | 737.0% | 30.9% | -12.0% | -9.4% | |
| Diluted Shares | 49.5% | 8.9% | 16.1% | 56.8% | 173.0% | 108.3% | 48.9% | 88.6% | 38.5% | 25.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High1.52 / 262.72 / 1143.94
P/B0.46
10Y Low / Med / High0.05 / 0.50 / 3.84
EV/EBITDA0.45
EV/Revenue0.00
10Y Low / Med / High0.11 / 241.62 / 1153.42
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$13.76
Net Current Assets / Share
$10.12
Graham Net-Net
$10.04
Cash / Share
$20.46
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.05 | -0.07 | -0.11 | -0.25 | -0.98 | -0.98 | -1.08 | -1.84 | -4.21 | -0.98 | -0.29 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 13.76 | 1.52 | 0.00 | 4.73 | 262.72 | 1143.94 | 383.20 | 0.00 | |
| P/B Ratio | 0.05 | 0.05 | 0.11 | 0.27 | 0.50 | 0.30 | 0.69 | 1.02 | 3.84 | 1.08 | 0.46 | |
| EV/EBITDA | 0.45 | -0.04 | 0.10 | -0.39 | -0.08 | -0.99 | -1.16 | -1.79 | -4.34 | -1.02 | 0.45 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 19.73 | 0.11 | 0.00 | 4.88 | 241.62 | 1153.42 | 389.99 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-17.07
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.9M | $8.8M | $3.9M |
| Net Income | -$38.3M | -$34.8M | -$32.8M |
| EPS | $-16.46 | $-14.97 | $-14.67 |
| # Analysts (EPS) | 4 | 5 | 6 |
Revenue Segments
By Product
| Segment | 2025 |
|---|---|
| Collaboration Revenue | $200.0K |